Bruce E. Johnson

87.4k total citations · 15 hit papers
420 papers, 50.6k citations indexed

About

Bruce E. Johnson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Bruce E. Johnson has authored 420 papers receiving a total of 50.6k indexed citations (citations by other indexed papers that have themselves been cited), including 267 papers in Pulmonary and Respiratory Medicine, 255 papers in Oncology and 112 papers in Molecular Biology. Recurrent topics in Bruce E. Johnson's work include Lung Cancer Treatments and Mutations (239 papers), Lung Cancer Research Studies (129 papers) and Lung Cancer Diagnosis and Treatment (78 papers). Bruce E. Johnson is often cited by papers focused on Lung Cancer Treatments and Mutations (239 papers), Lung Cancer Research Studies (129 papers) and Lung Cancer Diagnosis and Treatment (78 papers). Bruce E. Johnson collaborates with scholars based in United States, United Kingdom and France. Bruce E. Johnson's co-authors include Pasi A. Jänne, Matthew Meyerson, Neal I. Lindeman, Michael J. Eck, Titus J. Boggon, David M. Jackman, Sean Tracy, Jeffrey A. Engelman, Jeffrey C. Lee and Katsuhiko Naoki and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Bruce E. Johnson

402 papers receiving 49.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 7.5k citations J. Guillermo Paez, Pasi A. Jänne et al. Science profile →
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 3.6k citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science profile →
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

2005 3.2k citations Titus J. Boggon, Pasi A. Jänne et al. profile →
A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types

1994 2.3k citations Bruce E. Johnson et al. Science profile →
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

2001 2.0k citations Eugene J. Mark, Bruce E. Johnson et al. profile →
TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 1.2k citations Roy S. Herbst, Bruce E. Johnson et al. profile →
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 1.2k citations Bruce E. Johnson, Roy S. Herbst et al. profile →
Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission

1999 1.2k citations Bruce E. Johnson et al. profile →
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

2017 948 citations Bruce E. Johnson et al. profile →
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

2008 661 citations Lecia V. Sequist, Pasi A. Jänne et al. profile →
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

2009 644 citations David M. Jackman, Jeffrey A. Engelman et al. profile →
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

2016 612 citations Bruce E. Johnson et al. profile →
Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population

2009 526 citations Scott J. Rodig, Mari Mino–Kenudson et al. Clinical Cancer Research profile →
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

2005 499 citations Bruce E. Johnson et al. Clinical Cancer Research profile →
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

2016 334 citations Bruce E. Johnson et al. profile →

Peers

Countries citing papers authored by Bruce E. Johnson

Since Specialization

Citations

This map shows the geographic impact of Bruce E. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce E. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce E. Johnson more than expected).

Fields of papers citing papers by Bruce E. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce E. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce E. Johnson. The network helps show where Bruce E. Johnson may publish in the future.

Co-authorship network of co-authors of Bruce E. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce E. Johnson. A scholar is included among the top collaborators of Bruce E. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce E. Johnson. Bruce E. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Calls to action on lung cancer management and research 2024 ·The Oncologist ·(unknown), Fred R. Hirsch, Paul A. Bunn, Peter Ujházy, (unknown), Christine D. Berg, David P. Carbone, Balázs Halmos, Harpreet Singh, Hossein Borghaei, Andrea Ferris, Corey J. Langer, Sanja Đačić, Tony Mok, Solange Peters, Bruce E. Johnson	1
2	LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC) 2024 ·Annals of Oncology ·(unknown), M-J. Ahn, (unknown), Ibiayi Dagogo‐Jack, (unknown), Francesco Gelsomino, (unknown), (unknown), (unknown), (unknown), (unknown), Michael Offin, (unknown), (unknown), (unknown), Anne S. Tsao, (unknown), Tiziana Usari, Keith D. Wilner, Bruce E. Johnson	2
3	Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Joao V. Alessi, Adam Price, Allison L. Richards, Biagio Ricciuti, Xinan Wang, Arielle Elkrief, Federica Pecci, Alessandro Di Federico, (unknown), Emily S. Lebow, Patricia Mae G. Santos, Maria Thor, Andreas Rimner, Adam J. Schoenfeld, Jamie E. Chaft, Bruce E. Johnson, Daniel R. Gomez, Mark M. Awad, Narek Shaverdian	5
4	Association between Smoking History and Tumor Mutation Burden in Advanced Non–Small Cell Lung Cancer 2021 ·Cancer Research ·Xinan Wang, Biagio Ricciuti, Tom Nguyen, Xihao Li, Michael S. Rabin, Mark M. Awad, Xihong Lin, Bruce E. Johnson, David C. Christiani	85
5	Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing 2021 ·JCO Precision Oncology ·(unknown), Israel Gomy, (unknown), Alexander Gusev, Bruce E. Johnson, Neal I. Lindeman, Laura E. MacConaill, Shridar Ganesan, Judy E. Garber, Hossein Khiabanian	9
6	Visual Studio Code 2019 ·Bruce E. Johnson	1
7	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer 2018 ·Clinical Cancer Research ·Ibiayi Dagogo‐Jack, Pablo Martínez, Beow Y. Yeap, Chiara Ambrogio, Lorin A. Ferris, Christine Lydon, Tom Nguyen, Nicholas A. Jessop, A. John Iafrate, Bruce E. Johnson, Jochen K. Lennerz, Alice T. Shaw, Mark M. Awad	80
8	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial 2016 ·Clinical Cancer Research ·Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O’Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. Johnson, Daniel B. Costa, David M. Jackman, Pasi A. Jänne	92
9	Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer 2016 ·Clinical Cancer Research ·Curtis R. Chong, Magda Bahcall, Marzia Capelletti, Takayuki Kosaka, Dalia Ercan, Taebo Sim, Lynette M. Sholl, Mizuki Nishino, Bruce E. Johnson, Nathanael S. Gray, Pasi A. Jänne	67
10	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib 2015 ·Clinical Cancer Research ·Monique B. Nilsson, Uma Giri, Jayanthi Gudikote, Ximing Tang, Wei Lü, Hai T. Tran, You-Hong Fan, Andrew B. Koo, Lixia Diao, Pan Tong, Jing Wang, Roy S. Herbst, Bruce E. Johnson, Andy Ryan, Alan Webster, Philip Rowe, Ignacio I. Wistuba, John V. Heymach	10
11	Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer 2013 ·Clinical Cancer Research ·Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen, Christine Lydon, Beow Y. Yeap, Lynette M. Sholl, Bruce E. Johnson, Pasi A. Jänne	274
12	Cetuximab Response of Lung Cancer–Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization 2013 ·Cancer Research ·Jeonghee Cho, Liang Chen, Naveen F. Sangji, Takafumi Okabe, Kimio Yonesaka, Joshua M. Francis, Richard Flavin, (unknown), Jihyun Kwon, Soyoung Yu, Heidi Greulich, Bruce E. Johnson, Michael J. Eck, Pasi A. Jänne, Kwok‐Kin Wong, Matthew Meyerson	86
13	A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry 2010 ·Clinical Cancer Research ·Mari Mino–Kenudson, Lucian R. Chirieac, (unknown), Jason L. Hornick, Neal I. Lindeman, Eugene J. Mark, David Cohen, Bruce E. Johnson, Pasi A. Jänne, A. John Iafrate, Scott J. Rodig	327
14	Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non–Small Cell Lung Cancer 2009 ·Clinical Cancer Research ·Emer O. Hanrahan, Anderson J. Ryan, Helen Mann, S. Kennedy, Peter Langmuir, Ronald B. Natale, Roy S. Herbst, Bruce E. Johnson, John V. Heymach	69
15	Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population breakdown → 2009 ·Clinical Cancer Research ·Scott J. Rodig, Mari Mino–Kenudson, Sanja Đačić, Beow Y. Yeap, Alice T. Shaw, Justine A. Barletta, Hannah Stubbs, (unknown), Neal I. Lindeman, Eugene J. Mark, Pasi A. Jänne, Thomas J. Lynch, Bruce E. Johnson, A. John Iafrate, Lucian R. Chirieac	526
16	Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers 2008 ·Clinical Cancer Research ·Kimio Yonesaka, Kreshnik Zejnullahu, Neal I. Lindeman, (unknown), David M. Jackman, Feng Zhao, Andrew M. Rogers, Bruce E. Johnson, Pasi A. Jänne	96
17	MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling breakdown → 2007 ·Science ·Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, (unknown), Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne	3570
18	Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models 2007 ·Cancer Research ·Hongbin Ji, Zhenxiong Wang, Samanthi A. Perera, Danan Li, Mei‐Chih Liang, Sara Zaghlul, Kate McNamara, Liang Chen, Mitchell Albert, Yanping Sun, Ruqayyah Al-Hashem, Lucian R. Chirieac, Robert F. Padera, Roderick T. Bronson, Roman K. Thomas, Levi A. Garraway, Pasi A. Jänne, Bruce E. Johnson, Lynda Chin, Kwok‐Kin Wong	137
19	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib 2006 ·Clinical Cancer Research ·David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal I. Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balázs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne	491
20	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy breakdown → 2004 ·Science ·J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J. Kaye, Neal I. Lindeman, Titus J. Boggon, Katsuhiko Naoki, Hidefumi Sasaki, Yoshitaka Fujii, Michael J. Eck, William R. Sellers, Bruce E. Johnson, Matthew Meyerson	7539

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact